摘要
[目的14g讨阿达木单抗治疗强直性脊柱炎(AS)患者的临床疗效及对生活质量的影响。[方法]本院收治的As患者42例,均接受阿达木单抗治疗24周,比较治疗前后各项临床、实验室指标以及生活质量评价指标的差异。[结果]患者治疗后的视觉模拟评分(VAS)、晨僵时间、BathAS活动指数(BASDAI评分)、As活动评分(ASDAS评分)、病人总体评价(PGA评分)均低于治疗前,且差异具有显著性(P〈0.01);患者治疗后的C反应蛋白(CRP)、血小板计数(PLT)、抗体IgG、IgM、IgA均低于治疗前,且差异具有显著性(P〈0.05);患者治疗后的生理功能、心理功能、社会功能、自我认识评分均高于治疗前,且差异具有显著性(P〈0.05)。[结论]As患者经阿达木单抗治疗后各临床和实验室指标均得到改善,临床效果较好且患者的生活质量明显提高。
[Objective]To investigate the clinical effect of Adalimumab treatment on ankylosing spondylitis patients and its impact on quality of life. [Methods] 42 cases of ankylosing spondylitis patients received Adali- mumab treatment for 24 weeks at our hospital. The differences in clinical and laboratory indexes as well as quality of life of the patients before and after treatment were compared, and the clinical efficacy of Adalimum- ab in the treatment of ankylosing spondylitis patients was evaluated. [Results]VAS(Visual analogue scale) scores, morning stiffness, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI score), Ankylo- sing Spondylitis Disease Activity scores (asdas scores), and patient global assessment (PGA) scores of pa- tients after treatment were lower than those before treatment, and the difference had statistical significance ( P〈0.05). The CRP, PLT, ESR, IgG, IgM, and IgA of patients after treatment were lower than those be- fore treatment, and the difference has statistical significance ( P〈0.05).The scores of physiological function, psychological function, social function, and the self-understanding of patients after treatment were higher than treatment before, and the difference has statistical significance( P〈0.05). [Conclusion]The clinical and labo- ratory parameters of ankylosing spondylitis patients were improved after treatment with Adalimumab the clinical effect was better and the quality of life was significantly improved.
出处
《医学临床研究》
CAS
2016年第8期1544-1546,共3页
Journal of Clinical Research